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ABSTRACT
Introduction: Glucose-6-phosphate dehydrogenase (G6PD) deficiency causes red blood cell destruction due to oxi-
dative stress. G6PD is essential for NADPH conversion; which is critical for glutathione reductase to prevent damage 
to cellular structures. In Malaysia, blood donors are not routinely screened for G6PD deficiency. We hypothesise that 
G6PD-deficient red blood cells are more likely to haemolyse during storage due to increased oxidative molecules. 
The objectives of this study were to determine the prevalence of G6PD deficiency among blood donors, describe 
their characteristics and to evaluate the effects of storage on G6PD-deficient donated blood. Methods: This study was 
conducted at selected mobile donation centres in Terengganu. Consented blood donors were screened for G6PD sta-
tus using fluorescent spot tests (FST). G6PD enzyme activities were measured for donors who were G6PD deficient. 
Effects of storage on haemolysis from G6PD-deficient donors were compared with non G6PD-deficient group. Sixty 
ml of blood was collected from blood unit to transfer pouch for estimation of haemoglobin (Hb), plasma Hb, per-
centage of haemolysis and plasma potassium. Serial sampling with a 7-day interval was done from Day 1 to Day 35. 
Statistical analysis was considered significant if p ≤0.05. Results: A total of 440 blood donors were screened and 12 
male donors were found to be G6PD deficient by FST. Enzymatic activities were measured in 11 donors as one donor 
sample failed to be sent to the centre due to logistic problem. Their enzymatic activities ranged from 1.66-2.93 U/g 
Hb whereby 6 have severe deficiency and the other 5 were categorised as partial deficiency. Donors were asymp-
tomatic for haemolytic episode. Serial sampling showed there was no significant difference of haemolytic parameters 
in blood units of G6PD-deficient donors as compared to control (p>0.05).  Conclusion: Prevalence of G6PD blood 
donors in Terengganu mobile centres was 2.7%. G6PD enzyme activities did not correlate with clinical symptoms. 
Haemolytic parameters were not affected in blood units which were G6PD-deficient.
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INTRODUCTION
The most common enzymopathy disease in the 
world is glucose-6-phosphate dehydrogenase (G6PD) 
deficiency. It is characterised by destruction of red blood 
cells (RBC) when exposed to oxidative stress caused by 
infection and ingestion of certain medications or food. 
The prevalence of G6PD deficiency worldwide is 4.9%. 
The geographical distribution of this disease is wide 
and has variable prevalence in different countries (1). 
In Malaysia, the overall prevalence of G6PD deficiency 
was 3.4 %; among which 5.3 % are males and 1.1% are 
females (2). 
Oxidative stress on RBC may precipitate individuals 
with G6PD deficiency to present with neonatal jaundice 
and acute haemolytic anaemia. Causes of oxidative 
stress can be due to infection, some medications, or 
fava beans ingestion (3). Unfortunately, individuals who 
are G6PD-deficient usually are not aware of their status 
throughout their lives as most of them do not produce 
any symptoms; hence, the extent of the issue may be 
underrated (4).
The prevalence of G6PD deficiency among blood 
donors around the world has been reported and the 
frequency varies significantly. As the prevalence of 
G6PD deficiency depends on their racial or ethnic 
composition, this also affect the prevalence among 
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donors. In Malaysia, to the best of our knowledge, 
there is no published report on the prevalence of G6PD 
deficiency among blood donors. 
There is dispute with regards to whether individuals with 
G6PD deficiency should be allowed to donate blood 
(5) and issues related to the value of donated blood 
during handling and storage (6). However, presence 
of G6PD deficiency is not an exclusion criterion in 
the selection of blood donors. According to the World 
Health Organization (WHO), they suggest that without 
history of haemolysis, blood donors with G6PD 
deficiency are eligible to donate their blood. However, 
the donated blood from those individuals cannot be 
used for intrauterine transfusion, exchange transfusion 
in neonates or for patients with G6PD deficiency. WHO 
also recommends that, those G6PD-deficient donors 
with a history of haemolysis are deferred from donating 
their blood (7). A similar approach has been adopted by 
the Malaysian National Blood Centre (8). 
However, during the donation process, blood donors are 
not routinely screen for G6PD deficiency (5). Since most 
of individuals with G6PD deficiency are asymptomatic 
especially those with mild reduction in G6PD activity, 
blood donors are not aware that they may be a carrier of 
G6PD deficiency.
Current blood banking practice allows refrigerated 
storage of RBC for up to 42 days prior to transfusion. 
Standard processing and storage of RBC is accompanied 
by increased reactive oxygen species and accumulation 
of oxidative biomarkers with prolonged storage. As 
G6PD-deficient RBC lack the ability to cope with these 
oxidative stresses caused by refrigerated storage (9), our 
hypothesis is that G6PD-deficient RBC will accumulate 
more oxidative damage than G6PD-normal RBC during 
storage, thereby resulting in increased in haemolysis and 
potassium levels; thereby rendering the unit unsuitable 
for use and may cause detrimental effects to recipient 
if transfused. In previous research related to G6PD-
donated blood, these blood units were subjected to 
methods which enhance RBC injuries (10, 11) and 
findings were conflicting. To our knowledge, there is 
no study which investigates the effect of conventional 
storage on G6PD donated blood units. 
In light of these observations, the aim of this study 
is to determine the prevalence of G6PD-deficient 
blood donors, describe their clinical characteristics 
and determine the effects of storage on haemolytic 
parameters of G6PD-deficient blood.
 
MATERIALS AND METHODS
Ethical approval
This study was conducted at selected mobile donation 
centres in Terengganu and Department of Pathology, 
Hospital Sultanah Nurzahirah, Kuala Terengganu. 
Institutional ethical approval was granted by Universiti 
Putra Malaysia (FPSK(FR15)P018) and Ministry of Health 
Medical Research Ethical Committee (NMRR-14-1730-
22998). Written informed consent was obtained from all 
donors prior to participation in the study.
Study population and sampling
Blood donors who attended the Mobile Blood Donation 
centres from August 2015 to February 2016 were 
invited to participate in the study. Using the prevalence 
of G6PD deficiency in Malaysia from a previous study 
(2), the sample size for this study was calculated to 
be 202.  Generally, all voluntary and non-numerated 
blood donors had to answer a health questionnaire in 
the standard blood donation form and an interview 
before the donation procedure. A systematic sampling 
method was adopted. Every third donor was invited 
to participate in this study. Eligible blood donors were 
included in the study if they consented to participate 
after detailed explanation by the researcher. Donors 
with medical histories of red cell disorders e.g. red 
cell enzymopathy or membranopathy, thalassaemia 
or haemoglobinopathy or on oxidative or red cell 
haemolysing drugs were excluded from the study.
Blood sampling
Approximately 2.5 ml of venous blood samples were 
collected in ethylene diamine tetraacetic acid (EDTA) 
containers (BD Vacutainer®, USA) for G6PD screening 
from all respondents. 
G6PD-deficient blood bags as well as the normal G6PD 
blood bags were identified. Only 50-60 ml of blood was 
taken from the principal bag and separated into the transfer 
bag, allowing the remaining blood in the principal bag 
to be used for future transfusion. Subsequent analysis 
of blood parameters were from the transfer bag with 
equivalent ratio of preservatives, stored separately from 
the principal bag. Approximately six ml of blood sample 
were collected from the transfer bag on days 1, 7, 14, 
21, 28 and 35 for serial measurement of plasma and 
blood haemoglobin, haematocrit, and potassium level 
(Figure 1). Serial seven-day intervals measurement was 
modified from Kanias & Gladwin, 2012 (12). Samples 
for testing were collected by transferring the blood from 
the transfer bag into respective EDTA and plain tubes 
using the closed docking system.
G6PD screening and confirmation
The fluorescent spot test (FST) was used for G6PD 
screening to determine prevalence of G6PD deficiency 
among the blood donors. 
For semi-quantitative FST, a drop of whole blood from 
each sample) was dried on Whatman’s filter paper. The 
detailed procedure of the FST is found in Beutler,E. (1994) 
(13). Samples with normal or slightly depressed G6PD 
activity show strong fluorescence. No fluorescence 
after a 10-minute incubation period suggests complete 
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lack or marked deficiency of G6PD. This test was run 
together with an internal positive and negative control.
Quantitative G6PD test was performed if the FST showed 
deficient or intermediate results. This test confirms the 
reduced G6PD activity in G6PD-deficient blood donors. 
The test was performed in the Haematology Laboratory, 
Department of Diagnostic Laboratory Services, Hospital 
Canselor Tuanku Mukhriz (HCTM). The samples from 
the EDTA bottles were sent to HCTM and processed 
within 72 hours of collection to measure G6PD enzyme 
activity. 
The OSMMR2000-D G6PD assay kit (R&D Diagnostics 
Holargos, Greece) with haemoglobin normalisation 
was used to quantitate G6PD enzyme activity using 
a spectrophotometer (Ultramicroplate Reader EL808, 
Bio Tek, Instruments). Principle of this kit involved an 
enzymatic colorimetric method for the quantitative 
determination of G6PD activity that employs the 
haemoglobin normalisation procedure. Detailed 
procedure of this quantitative G6PD test is found in 
Azma et al (2010) (14). 
This assay kit was also governed by external QC (RCPA) 
& internal QC runs periodically as stated by the standard 
operating procedure.
Haemoglobin, plasma haemoglobin, haematocrit and 
percentage of haemolysis measurement
Effects of red blood cell storage upon red cell haemolysis 
were determined using the following parameters.  All 
these parameters are measured using automated 
analyser, Sysmex XN-1000 series. This analyser has 
been evaluated and validated for use and is governed by 
external QC (RCPA) & internal QC runs periodically as 
stated by the standard operating procedure.
Measurement of haemoglobin and plasma haemoglobin 
were performed using Sysmex XN-1000.  The 
measurement principle used is sodium lauryl sulphate 
(SLS)-haemoglobin method. This method uses SLS for 
measuring the haemoglobin concentration. SLS binds to 
the red blood cell membrane mainly by ionic bonding 
and partly by hydrophobic bonding. SLS- haemoglobin 
shows absorption curve with the maximum peak at 
wavelength 535 nm and a shoulder peak at 560 nm. 
The analyser irradiates light of 555 nm wavelength and 
measures the absorption.
Plasma haemoglobin is also measured using the similar 
principle whereby plasma is separated first from the 
red blood cells, and then haemoglobin in the plasma is 
measured.
Haematocrit (HCT) is a measurement of the ratio of 
the capacity occupied by the red blood cells to the 
volume of whole blood. Haematocrit is calculated by 
an automated analyzer by multiplying the red cell count 
by the mean cell volume (MCV).
As for percentage of red cell haemolysis, the following 
formula was used; 
         Haemolysis = Plasma Hb x 1-Hct x 100B-hb 
where Hb- haemoglobin; Hct- haematocrit; B-hb- blood 
haemoglobin.
Potassium level measurement
The Beckman Coulter AU5800 biochemistry analyser 
was used to measure RBC potassium levels in stored 
donated blood. This analyser has been evaluated 
and validated and also took part in External Quality 
Control (EQC) by RCPA. Internal Quality Control (IQC) 
runs periodically as stated by the standard operating 
procedure.
The AU5800 analyser is a fully automated system for 
clinical chemistry analysis intended for the in vitro 
quantitative determination of analytes in body fluid. 
Potassium is measured using ion-selective electrodes.
Statistical Analysis
Data were entered and analysed using statistical package 
programme SPSS version 22.0 windows. Descriptive 
statistics for categorical variables were expressed as 
frequency and percentage whereas numerical variables 
were expressed as median and inter quantile range (IQR) 
for assumed not normally distributed data (as samples 
analysed less than 30). We used Mann Whitney U test 
to compare the median between the two independent 
variables. A p- value of < 0.05 was considered significant.
RESULTS  
Demographic data of blood donors
The sociodemographic characteristics of respondents 
are summarised in Table I. Most of the participants were 
male donors (70.2%) and female donors accounted for 
29.8%. Most of them were Malay (93.9%), followed by 
Chinese (4.1%), Indian (0.9%) and others (1.1%). The 
mean (standard deviation) age of blood donors was 
23.19 (7.16) years old. About 300 (68.2%) were first 
Figure 1: Flow chart of the methodology 
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time donors and others had 2 times donation per year 
(20.4%) and regular donors who donate more than 2 
times per year were 11.4%.  
Prevalence of G6PD deficient blood donors and their 
severity 
There were only 12 (2.7%) donors among the 440 
samples collected found to have G6PD deficiency from 
the G6PD screening test. Among the G6PD deficient 
blood donors, we were able to measure G6PD enzyme 
activities in 11 out of 12 respondents as one sample 
failed to be sent to the referral lab within 72 hours due 
to logistic problem. The mean G6PD enzyme value was 
2.24 (0.93) unit/g Hb (Table II).
G6PD deficiency was classified by severity based on its 
enzymatic activity whereby; severe deficiency is when 
enzyme activity is less than 20% of mean normal activity 
and partial deficiency is where its activity is 20-60% of 
mean normal activity. Out of 11 respondents, 5 (46%) 
of them had partial G6PD deficiency while another 6 
(54%) of them had severe G6PD deficiency. Enzyme 
levels for G6PD-deficient partial and severe deficiency 
donors were 2.93 (0.91) [ref range: 2.36-7.27 Unit/g 
Hb] and 1.66 (0.40) Unit/g Hb [ref range < 2.36 Unit/g 
Hb], respectively. The range stated were 20% of normal 
mean equivalent to 2.36 U/gHb and 60% of mean 
normal activity equivalent to 7.27 U/gHb measured 
during the period of the study. Severe deficiency was 
Table I: Demographic data and donation status of blood donors 
(n=440)
Variable Mean (SD)*
Age (years) 23.19 (7.16)
Frequency n(%)
Gender
Male 309 (70.2)
Female 131 (29.8)
Ethnic
Malay 413(93.9)
Chinese 18(4.1)
Indian 4 (0.9)
Others 5(1.1)
Number of donation per year
First time donor 300 (68.2)
2 times per year 90 (20.4)
More than 2 times per year 50 (11.4)
*SD- standard deviation
diagnosed when the level was less than 20% equivalent 
to less than 2.36 U/gHb.
Demographic data of G6PD deficient blood donors by 
enzymatic activity
Out of 11 donors with G6PD deficiency, all of them 
(100%) were Malay male donors. The mean age was 
21.6 (5.7) years old. Six (54.5%) of them were first-time 
donors followed by 4 (36.4%); who donated 2 times per 
year and 1 (9.1%) were those who donated more than 2 
times per year. All G6PD deficient donors in this study 
were asymptomatic of haemolytic episodes. None of the 
11 respondents were aware of being G6PD deficiency 
carriers, including the five who were periodic donors 
(45.5%).
Effect of storage on haemolytic parameters in G6PD-
deficient donated blood compared to normal G6PD
Table III summarises the effect of storage on haemolysis 
parameters in blood from 11 G6PD-deficient donors as 
compared to 11 G6PD normal donors. 
Table II: Severity of G6PD deficiency among G6PD deficient blood 
donors
G6PD deficient 
blood donors 
n, (%)
G6PD enzyme ac-
tivity Mean (SD) 
(Unit/g Hb)
Reference 
range (Unit/g 
Hb)
Partial deficiency 5 (46%) 2.97 (0.91) 2.36-7.27
Severe deficiency 6 (54%) 1.66 (0.40) <2.36
Notes: Calculation of reference range for adult was based on WHO Working Group 1989 
(Value of more than 60% of normal mean is considered to be the normal value of G6PD 
enzyme)
Table III: Effect of storage on haemolysis parameters in blood from 
G6PD normal donors compared G6PD deficient blood donors
Time G6PD- Normal G6PD-Deficient p value (Mann 
Whitney U test)
Days Median IQR* Median IQR*
Haemoglobin level (g/L)
1 169.0 51.8 151.5 90.8 0.762
7 181.5 49.3 153.5 88.0 0.597
14 180.0 58.5 210.0 74.3 0.212
21 172.0 69.3 160.5 98.3 1.0
28 165.0 73.5 151.5 95.3 1.0
35 173.5 66.5 153.5 85.5 1.0
Plasma Haemoglobin level (g/L)
1 0 0 0 0 0.146
7 0 0.3 0 1.0 0.3
14 0 1.0 0 1.0 0.445
21 0 1.0 0 1.0 0.923
28 0 1.0 0 1.5 1.0
35 0.5 2.0 0 2.5 0.854
Percentage of haemolysis (%)
1 0 0 0 0 0.147
7 0 0.05 0 0.25 0.351
14 0 0.16 0 0.16 0.901
21 0 0.20 0 0.23 0.813
28 0 0.19 0 0.31 0.777
35 0.27 0.44 0 0.30 0.353
Potassium level (mmol/L)
1 5.45 1.44 4.67 1.52 0.762
7 14.54 12.53 11.25 3.97 0.496
14 22.79 14.52 16.11 8.77 0.288
21 27.17 17.21 19.89 7.76 0.142
28 24.96 17.03 22.12 9.37 0.414
35 35.23 20.45 26.24 9.09 0.514
*IQR- interquartile range
p value > 0.05 – not significance.
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DISCUSSION
Sociodemographic characteristics of blood donors
In this present study there were 309 (70.2%) male donors 
whilst 131 (29.8%) were female donors. This is similar 
to the worldwide trend of more male blood donors 
than female blood donors.  Malaysia has multiracial 
population with Malays, Chinese and Indians being the 
major ethnics in Peninsular Malaysia. In Terengganu, we 
found that Malay blood donors were the highest (93.9%) 
followed by Chinese (4.1%), Indian (0.9%) and others 
(1.1%). Our result was consistent with a study done by 
Rosline et al which reported 91.3% of blood donors 
were among Malays (15) and report from population 
census whereby 97% of Terengganu population were of 
Malay ethnicity (16). The mean age (SD) of blood donors 
was 23.19 (7.16) years old. This showed that majority of 
the blood donors were among the younger age group.  
 
Prevalence of G6PD deficient blood donors and severity 
of G6PD deficiency 
In this study, we found that prevalence of G6PD 
deficiency in blood donors is 2.7%. The reported 
proportions of G6PD deficiency among blood donors 
worldwide varies significantly; Nigeria (19.5%) (18), 
Canada (0.17%) (19), Brazil (3.2%) (20), Iran (16.3%) 
(21), India (0.8%) (22), Riyadh, Saudi Arabia (0.78%) (6), 
Italy (1.1%) (23) and United States (0.3%) (5). This shows 
diversity in study population and background affects 
prevalence of G6PD deficiency among population 
as well as its prevalence among blood donors. G6PD 
deficiency is highly diverse, with at least 217 genetic 
variants expressing a spectrum of enzyme phenotypes. 
At the global scale, distinct regional patterns of G6PD 
deficiency epidemiology emerge based on unique 
combination of alleles originating from different regions 
(24).
WHO Working Group in 1989 defined G6PD deficiency 
as a residual red cell G6PD activity level of less than 
60% normal (25). Individuals with activity of < 20% of 
mean normal activity is called severe deficiency and 
those with 20-60% of mean normal activity; they are 
classified as partial deficiency (26). 
In this study, all G6PD deficient blood donors were 
male. Out of 11 G6PD deficient donors assessed; 54% 
(6 of 11) had severe enzyme deficiency and 46% (5 of 
11) had moderate enzyme deficiency with the values 
for G6PD activities of 1.66 (0.40) and 2.93 (0.91) U/
gHb, respectively. Differences in the level of G6PD 
enzyme among G6PD deficient males’ donor are most 
probably due to different G6PD variant they have. The 
most common G6PD variant causing G6PD deficiency 
belongs to the class II variant in which the enzyme is 
severely deficient. Previous local study reported among 
Malay and Chinese neonates with G6PD enzyme 
deficiency, majority of them were males with severe 
enzyme deficiency (27, 28). Similarly in this study, more 
Blood haemoglobin
Figure 2 compares haemoglobin levels between G6PD-
deficient and normal G6PD blood based on storage time 
(days). Even though the value of blood haemoglobin in 
the G6PD-deficient group were lower than normal G6PD 
group in most measured days, statistical analysis using 
Mann Whitney U test showed there is no significance 
difference during storage of both G6PD-deficient and 
normal G6PD blood (p value > 0.05).
Free plasma haemoglobin & percentage of haemolysis
As for free plasma haemoglobin and percentage of 
haemolysis, free plasma haemoglobin and haemolysis 
were not detected in both groups of normal G6PD and 
deficient G6PD blood with time upon storage, hence 
there was no statistical significance noted in both 
parameters.
Plasma potassium
Figure 3 shows an increasing trend of potassium level 
upon storage in both groups of normal G6PD and deficient 
G6PD blood. Potassium levels were consistently lower 
in the G6PD-deficient group as compared to normal 
G6PD. However, there was no significant differences (p 
>0.05) when values of both groups were compared.
Figure 2: Effect of storage on blood haemoglobin level. Bar 
chart showing serial comparison of blood haemoglobin level of 7- day 
interval between blood donated by normal G6PD donors (blue) and 
deficient G6PD (green). There is no significant change in both groups 
with regards to blood haemoglobin level (p > 0.05)
Figure 3: Effect of storage on potassium level. Bar chart show-
ing serial measurement of potassium level of 7- day interval between 
blood donated by normal G6PD donors (blue) and deficient G6PD 
(green). There was increased in potassium level with increasing days 
of storage however, there is no significant change in both group (p> 
0.05)
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than half of the G6PD deficient were males with severe 
enzyme deficiency.
In another local study, they found the prevalence of 
partial enzyme deficiency in female children and female 
neonates were 15.7% and 3.42% respectively (29). 
However, no study was done among adult population 
to compare with our study. Therefore, there is possible 
underestimation in our prevalence of G6PD deficiency 
especially among the partial deficient female donors 
as we did not use the quantitative enzyme assay as the 
screening method.
The risk of haemolytic episode is not critically 
dependent on the true level of the G6PD enzyme alone. 
In affected males, as they can only be hemi zygotes of 
G6PD deficiency, they have always been associated 
with high risk of haemolysis. Nevertheless, even in 
partially deficient individuals, there is increased risk of 
oxidative haemolysis when exposed to certain drugs, 
food, chemicals, infection and not to mention cultural 
practices (30). The clinical severity of G6PD deficiency 
also depends on the different type of G6PD variants. 
Specific G6PD allele mutations give rise to variable 
sensitivity against oxidative damage. In some cases with 
extremely low enzyme level, chronic haemolysis may 
occur (31). However, effects of haemolysis on blood 
storage between these partial and severe deficiency has 
not been determined yet in the literature.
Socio demographic and clinical characteristics of 
G6PD deficient blood donors 
Sex distribution in this study showed that 100% of the 
deficient donors were male. This is because the gene 
that expresses G6PD enzyme is located at chromosome 
X, hence, the male preponderance of the deficiency. An 
abnormality at specific alleles of X chromosome may 
give rise to G6PD deficiency. A female heterozygote has 
50% chances of passing the abnormal X chromosome to 
her son. Therefore, the son who receives the abnormal 
gene will be G6PD deficient. On the other hand, her 
daughter may be normal or a heterozygote carrier (15). 
As stated earlier, males are hemi zygotes of G6PD 
deficiency thus the enzyme activity is always low. 
Females on the other hand, may be heterozygous or less 
commonly homozygous for the G6PD gene mutation. 
In homozygous females, the enzyme activity can be as 
low as male hemizygotes. However, in heterozygous 
females, a lyonization phenomenon may occur. This 
phenomenon causes random inactivation of the normal 
X chromosome giving rise to genetic mosaicism in the 
red cells G6PD activities. The overall effect of the G6PD 
deficient severity depends on the proportion between 
deficient and normal residual red cells enzyme’s activity 
(23).
Another factor contributing to the absence of G6PD 
deficiency in female donors was due to the insensitive 
method used in this study. Female heterozygotes may 
have partial deficiency in which the enzyme level 
ranges between 20-60% (26). Previous study had shown 
that semi quantitative method like FST is not reliable to 
detect heterozygotes female as it is only sensitive when 
the enzyme activity is less than 20% (32). In this study, 
we used FST as first line to screen all donors followed 
by confirmatory test of red cell enzymatic activity 
quantitation. Semi quantitative method is reliable 
in detecting severe G6PD deficient but may missed 
substantial number of partial deficient donors. This 
reason may explain the possibility of missing partially 
G6PD deficient female blood donors in this study.
Based on racial distribution, from this study, we found 
that all G6PD deficient male donors are Malays. This 
is consistent with previous study which stated G6PD 
deficiency is more prevalent among Malays and 
Chinese, and less commonly occurred among Indian. 
The prevalence of G6PD deficiency among males was 
5.3%; with racial distribution of 7.2%, 4.6% and 2.7% 
among Chinese, Malays and Indians males respectively 
(2). 
In this study, none of the G6PD deficient donors was 
aware of their G6PD status even though half of them 
were periodic donors. They were also asymptomatic 
and admitted that there was no history of favism in the 
past. Similarly, few studies reported that most of the 
G6PD deficient blood donors are symptomless with no 
history of previous haemolytic reaction or jaundice due 
to febrile illnesses or drugs (33, 17, 18).
Effects of storage on levels of blood haemoglobin, 
plasma haemoglobin, percentage of haemolysis and 
potassium between G6PD deficient and normal G6PD 
blood
Markers of storage lesions assessed in this study include 
blood haemoglobin, plasma haemoglobin and potassium 
level. Haemolysis is defined as the breakdown or the 
disruption of red blood cells’ membrane integrity with 
subsequent release of haemoglobin to the plasma. 
Findings of the present study shows there were no 
significant differences in the effect of storage on 
haemolysis of G6PD deficient blood as compared to 
normal G6PD blood in any of the time interval assessed 
(p value > 0.05).
These findings are almost similar with findings of past 
study by Agarwal et al. whereby G6PD deficient red cells 
(cases) were irradiated by gamma rays and compared 
with red cells with normal G6PD (controls). Markers for 
storage lesion, such as, free plasma haemoglobin and 
potassium; as well as lactate dehydrogenase (LDH), 
were not elevated significantly following irradiation. 
Hence, it was concluded that, there was no significant 
extra damage to RBC membrane due to G6PD deficiency 
when subjected to gamma irradiation as compared to 
controls (10).  Although they used gamma irradiated 
blood to compare between these two groups, the final 
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findings were similar to our study; there was no different 
in the effects of storage on haemolysis of blood belonged 
to G6PD deficient individuals. 
In contrast to another study by Westerman et al, ionizing 
radiation had adverse effect on G6PD-deficient red cells 
and RBCs survival times were shortened when compared 
with normal red cells (11). The differences in results 
could occur due to variation in methodology such as 
differences in cut off level of G6PD activity in the RBCs 
(e.g., G6PD-deficient RBC with 10% versus 10%-60% 
residual enzymatic activity). Apart from that, variation 
in radiation dose and different methodologies used to 
assess G6PD deficiency (i.e., cesium-137 versus x-rays) 
also had to be considered. Materials used for blood 
storage also varies (blood bags vs plastic containers), 
as well as different variants of G6PD activity (because 
the type and degree of haemolysis differs according to 
variant) (10, 11). 
However, in our study, the blood under storage was 
not subjected to any method which may enhance the 
RBC injury, like previous studies. They used gamma 
irradiation on G6PD deficient red cells to induced 
oxidative injuries while in this study, the blood were 
stored in conventional condition without any addition 
of oxidative stress. 
The main characteristic of G6PD deficiency is RBC 
destruction in response to oxidative stress. Following 
blood donation, conventional blood storage system 
has factors which contribute to oxidative stress. These 
factors include presence of reactive oxygen, free radicals 
and other oxidative biomarkers that accumulates over 
time. An example of this is malondialdehyde and other 
products of oxidation from the human serum albumin, 
lipid as well as spectrin, which is on RBC membrane 
protein (34). Changes that occur during storage will 
contribute to haemolysis in vitro and in vivo. Oxidative 
damages do occur on normal RBCs during conservative 
blood banking storage. Main variations usually occur 
between 7 to 14 days of storage (12).  These consequences 
would most probably be increased with red cells which 
are G6PD deficient (13). However, other than G6PD 
deficient blood donor, storage injuries appear to be 
reliant on donor age, sex, smoking habit and may also 
be subjected by the other genetic background of the 
donor for example thalassemia traits (34) which are not 
specifically assessed in this study.
Haematological parameters which include blood 
haemoglobin, plasma haemoglobin and percentage 
of haemolysis can be used as quality indicators for 
stored blood. One of the most used quality indicator for 
stored red cell units is the extent of haemolysis. There 
are many factors that caused abnormal haemolysis 
in RBC units. These include inappropriate handling 
during processing and storage of blood, RBC membrane 
defects, complement lysis due to bacterial haemolysin 
antibodies or an abnormality in the blood donor (35). 
The extent of haemolysis is described as the percentage 
of free haemoglobin in relation to the total haemoglobin 
with appropriate correction for the haematocrit. 
Council of Europe and US FDA guidelines have stated 
that the allowable degree of haemolysis should not 
more than the permissible value which is 0.8% and 
1% respectively, even on the day of 42nd of storage 
(36). There was no sample in this study which showed 
percentage haemolysis of more than 0.8%, which is the 
maximum acceptable limit of haemolysis as per Council 
of Europe Guideline.
There was some discrepancy noted in the result of 
blood haemoglobin level at day 14 analysis. This was 
probably due to pre analytical error occurred during 
blood sampling for example improper mixing of blood. 
This will affect haemoglobin and haematocrit level 
.Another reason why these haematological parameters 
showed not much different between these two groups 
most probably because the blood donors with G6PD 
deficiency have normal haematological parameters 
thus, they are well, asymptomatic and unaware of their 
genetic defect especially those with mild to moderate 
level of G6PD enzyme. Even with severe G6PD 
deficiency due to class II molecular variant, they are 
often asymptomatic and haemolytic attacks are triggered 
only by an oxidative damage (3). Since the blood 
donors are asymptomatic and most of them have normal 
haematological parameters, this probably explained 
the storage lesions in both groups were almost similar 
throughout the storage time.
In a study to evaluate effect of blood storage on complete 
biochemistry, there were significant increase in serum 
phosphorus, AST, serum protein, calcium and potassium 
level and decrease in pH, serum chloride, sodium and 
bicarbonate levels throughout the storage time (37). 
Similarly, in our study, we noted the median value of 
potassium level increased during storage period in 
both groups. However, comparing G6PD deficient and 
normal G6PD blood, the difference was not statistically 
significant (p value > 0.05) for plasma potassium level.
Accumulation of potassium in the supernatant due to 
alteration of Na+/K+ fluxes in the older RBCs can cause 
adverse clinical consequences especially in paediatric 
patients (34).
CONCLUSION
From this study, as there was no difference in the 
effect of storage on haemolysis of G6PD deficient 
blood, screening for G6PD deficient donors appear 
to be unnecessary. There is a need to perform similar 
study with larger sample size, G6PD variant molecular 
characterization and more numbers of parameters taken 
into account for study of oxidative damages. Apart from 
that, there is a need to study about the effects of receiving 
G6PD deficient blood in the recipient. Although the 
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risks for most adult recipients are minimal, specific cases 
as in premature infant, neonates and in patients who 
may require multiple transfusions, screening for G6PD 
deficiency in the donors may be essential (4).
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